$1.65
-0.01 (-0.60%)
Open$1.66
Previous Close$1.66
Day High$1.77
Day Low$1.64
52W High$19.48
52W Low$10.45
Volume—
Avg Volume676.0K
Market Cap27.51M
P/E Ratio41.27
EPS$0.37
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+886.1% upside
Current
$1.65
$1.65
Target
$16.27
$16.27
$12.16
$16.27 avg
$21.27
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.83M | 3.86M | 4.10M |
| Net Income | -148,955 | -155,305 | -171,738 |
| Profit Margin | -3.9% | -4.0% | -4.2% |
| EBITDA | -206,512 | -205,551 | -243,961 |
| Free Cash Flow | -139,442 | -168,121 | -167,490 |
| Rev Growth | +3.3% | +19.6% | -4.2% |
| Debt/Equity | 1.04 | 0.81 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |